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Surveillance biopsies have contributed to the understanding
of the natural history of renal allograft lesions. Subclinical
rejection, defined as the presence of histological lesions,
indistinguishable from acute rejection in stable grafts, is
associated with progression of interstitial fibrosis and tubular
atrophy. The prevalence of subclinical rejection has
decreased as more powerful immunosuppressive treatments
have been introduced, suggesting that subclinical rejection
represents the degree of control of the alloimmune response.
However, non-immune factors such as donor age are also
associated with the prevalence of subclinical rejection,
suggesting that kidneys from older donors are more
susceptible to insult and have a reduced capacity for tissue
regeneration. Innate immunity has a crucial role in the
modulation of the inflammatory response during infection
and tissue damage. Mannose-binding lectin (MBL) is an
innate immune protein, the polymorphisms of which are
associated with infection, low-grade inflammation, diabetes,
and cardiovascular disease. However, the relationship
between MBL and disease is complex. For example, low MBL
level is associated with higher risk for diabetes, whereas in
patients with diabetes, high MBL level is associated with
more severe renal damage. In renal transplant patients, low
MBL levels are associated with an increased prevalence of
infection and diabetes, whereas high MBL levels are
associated with shortened graft survival. Although MBL is not
clearly associated with prevalence of acute rejection,
surveillance biopsy studies have shown that low MBL levels
are associated with subclinical rejection in kidney and the
heart, suggesting that MBL modulates the injury–repair
process of the allograft.
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Protocol biopsy studies have contributed to the under-
standing of the natural history of renal allograft lesions.
These studies have shown that histological damage precedes
the appearance of proteinuria or renal functional deteriora-
tion in different conditions such as subclinical rejection
(SCR), interstitial fibrosis/tubular atrophy (IF/TA), chronic
humoral rejection, recurrence of the primary disease, de novo
glomerulonephritis, or polyoma virus infection. Protocol
biopsy studies have shown that early histological lesions
constitute an independent predictor of graft outcome. Of all
these conditions, SCR has captured the interest of the
transplant community for a long period of time.1
SUBCLINICAL REJECTION AND GRAFT OUTCOME
The term SCR was coined in a study of serial protocol
biopsies in 1995 when immunosuppressive treatment con-
sisted of cyclosporine, azathioprine, and prednisone.2 In this
pioneering study, the prevalence of SCR at different time
points during the first year was over 50%. Accordingly,
different studies evaluated whether SCR was associated with
outcome. In serial protocol biopsy studies, the presence of
SCR in a first biopsy was associated with progression of IF/
TA, impairment of glomerular adaptation, and progression of
glomerulosclerosis in the second one,3,4 suggesting that early
inflammation favors progression of chronic lesions.
During the 90s, an association between the presence of
IF/TA and graft survival was consistently described in
protocol biopsy studies. Similarly, in 2005, an association
between SCR in 2-week protocol biopsies and graft survival
was also documented.5 More recently, it has been further
described that the association of inflammation and IF/TA in
protocol biopsies implies a poorer outcome than IF/TA or SCR
alone.6–8 Altogether, these observations suggest an association
between SCR and poor graft outcome, and raise the question
whether treatment of SCR may improve outcome.
PREVALENCE OF SUBCLINICAL REJECTION AND
IMMUNOSUPPRESSION
The potential benefit of SCR treatment was explored in a
randomized trial in patients receiving cyclosporine,
azathioprine, and prednisone. In the study group, patients
were biopsied at 1, 2, and 3 months and treated with steroid
boluses, whereas the control group was not biopsied and
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accordingly not treated. IF/TA at 6 months and serum
creatinine at 2 years were lower in the treatment group,
suggesting that treatment of SCR may improve graft outcome.9
However, introduction of tacrolimus and mycophenolate
reduced the prevalence of SCR to B10%,10,11 showing that
SCR can be prevented with more efficient immunosuppression.
In a study of serial protocol biopsies, it was observed that
reduction of SCR with tacrolimus and mycophenolate was also
associated with a lower prevalence of IF/TA at 1 year, in
comparison with cyclosporine-based regimens.3 Moreover, in a
randomized study comparing a calcineurin-based regimen,
either associated with mycophenolate mofetil or associated
with sirolimus, the sirolimus groups displayed a lower
prevalence of acute rejection and SCR during the first year
and a lower prevalence of IF/TA at 5 years.12 Altogether, these
data suggest that SCR prevention with more efficient
immunosuppression may improve graft outcome.
RISK FACTORS FOR SUBCLINICAL REJECTION
The close association between immunosuppressive treatment
and prevalence of SCR has favored the assumption that it
represents, at the histological level, the balance between
alloimmune response and efficiency of immunosuppressive
treatment. From the epidemiological point of view, it has
been described that the degree of sensitization and clinical
episodes of acute rejection preceding the protocol biopsy
constitute a risk factor for SCR, further reinforcing the
notion that SCR represents the intensity of the immune
response.1 However, non-immune factors are also associated
with SCR, such as donor age.5 Kidneys from older donors are
more susceptible to insult and have reduced capacity for tissue
regeneration.13 Thus, it is tempting to speculate that SCR may
not only reflect alloimmune response but also may reflect the
inflammatory response associated with tissue injury and repair.
INNATE IMMUNE ALTERATIONS, TISSUE DAMAGE, AND
TISSUE REPAIR
Innate immunity constitutes the first line of defense against
infection and has a major role in tissue repair.14 Few highly
conserved structures on microorganisms, that is, pathogen-
associated molecular patterns, are recognized by pattern
recognition receptors that are expressed on effector cells of
the innate immune system, such as macrophages, dendritic
cells, or B cells. This pattern recognition receptors can be
divided into three types: endocytic, signaling, and secreted.
Probably, the best-known secreted pattern recognition
receptors molecule is mannose-binding lectin (MBL) that
activates complement by the lectin pathway and favors
inflammation and phagocytosis at the site of infection.
Cellular necrosis or apoptosis that follows tissue injury is
characterized by the secretion of danger signals known as
alarmins, which are sensed by the innate immune system.
Recognition of alarmins triggers inflammation and favors
phagocytosis of necrotic and apoptotic cells. Once necrotic
and apoptotic cells have been cleared, inflammation fades
and tissue regeneration leads to injury healing.15,16
As the response to infection and tissue damage is similar,
pathogen-associated molecular patterns and alarmins are also
termed as danger-associated molecular patterns. Alterations
of the innate immune response are associated with inefficient
tissue healing, chronic inflammation, and autoimmune
disease due to exposure of intracellular antigens and
inefficient necrotic and apoptotic cell phagocytosis. All these
alterations may also contribute to renal damage after
transplantation.
MBL LEVELS AND DISEASE IN GENERAL POPULATION
Innate immune alterations are associated with the prevalence
and outcome of different diseases. Different polymorphisms
of the MBL gene have been described and all of them are
associated with decreased MBL levels and impaired MBL
function. However, the relationship between MBL and
disease is rather complex. Whereas low serum MBL levels
are associated with an increased prevalence of infection,
autoimmunity, diabetes, and cardiovascular disease, high
serum MBL levels are associated with a poorer outcome of
certain autoimmune diseases.17 An example is that low serum
MBL level is associated with higher risk for diabetes,18
whereas in patients with diabetes, high serum MBL level is
associated with more severe renal damage.19 Furthermore, in
acute tissue injury after renal ischemia reperfusion injury,
high serum MBL level is associated with more severe
functional deterioration.20
MBL LEVELS AND RENAL TRANSPLANT OUTCOME
In renal transplantation, an association between MBL
polymorphisms or low serum MBL levels and increased
susceptibility to cytomegalovirus, bacterial, or fungal infec-
tions has been reported in some,21–23 but not in all,
studies.24,25 Despite the higher incidence of infection in low
serum MBL patients, no association between MBL levels and
mortality has been described.26,27 On the contrary, an
association between high MBL serum levels and decreased
death-censored renal allograft survival has been observed.
The incidence of acute rejection was not associated with
serum MBL levels, but acute rejection was more often the
cause for graft failure in patients with high serum MBL levels,
suggesting that high MBL levels may be associated with severe
forms of acute rejection.26 Similarly, in kidney–pancreas
transplantation, allograft survival was lower in patients with
high serum MBL levels.28 In contrast, in heart transplanta-
tion, low MBL levels were associated with an increased
prevalence of acute rejection and transplant-associated
coronary artery disease.29 Taking all these data together, it
is difficult to interpret the apparent discrepancies between
kidney and heart transplantation. A difference between
kidney and heart transplants is that protocol biopsies are
usually used to monitor heart histology and, only in few
centers, to monitor renal allografts. Furthermore, transplant
vasculopathy is actively monitored in the heart by means of
coronariography or intravascular ultrasounds. Until now, no
studies have analyzed the association between histological
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damage in protocol renal allograft biopsies and serum MBL
levels.
In a recent study, we measured serum MBL levels after
transplantation in a cohort of consecutive renal transplants
and classified MBL as low or high according to tertile
distribution. The first tertile was considered as the low MBL
group and the two higher tertiles were considered as the high
MBL group. Despite the fact that donor and recipient
characteristics were similar between groups, and that the
prevalence of delayed graft function or acute rejection was
not different between groups, we observed that patients with
low MBL levels displayed more severe low-grade inflamma-
tion before transplantation as measured by serum levels
of soluble tumor necrosis factor receptor 2, suffered a
higher incidence of bacterial or fungal infections, and
showed an increased prevalence of new-onset diabetes after
transplantation.23
In the above-mentioned study, a 3-month surveillance
biopsy was done in patients with a stable serum creatinine
o200 mmol/l and without significant proteinuria (o1 g/day)
after obtaining informed consent. There were 60 out of 125
recruited patients with an adequate surveillance biopsy.
Histological examination of these biopsies according to the
Banff criteria led to the diagnosis of SCR in 7 of 18 (38.9%)
low MBL patients and in 3 of 42 (7.1%) high MBL patients
(P¼ 0.0054). Induction and maintenance immunosuppres-
sion was not different in patients with low and high
MBL levels (Table 1). This observation suggests that innate
immune alterations such as MBL deficiency may contribute
to the degree of inflammation of the renal allograft (Figure 1).
Thus, it is tempting to speculate that patients with low MBL
levels may have an impaired capacity for tissue repair leading
to more severe and prolonged inflammation.
CONCLUSION
Innate immune alterations modulate different comorbidities
in renal transplant patients and may influence graft outcome.
Despite this association, mechanisms linking innate immu-
nity and graft damage have not been clearly elucidated. In
one hand, it has been suggested that patients with high MBL
levels may suffer from more severe episodes of rejection,
whereas in other studies low MBL levels have been associated
with a higher prevalence of subclinical or clinical rejection.
Thus, the relationship between graft outcome and innate
immune alterations deserves further studies.
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